Core Viewpoint - The company, Innovent Biologics-B (09606.HK), is initiating a dual capital market strategy by planning to issue RMB ordinary shares and list on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant move in its capital market activities [1][2]. Group 1: Capital Market Actions - Innovent Biologics-B's stock price rose over 5% on October 20, closing up 1.74% at 340 HKD, with a market capitalization nearing 30 billion HKD following the announcement of its plan to list on the Sci-Tech Innovation Board [2]. - The company went public on the Hong Kong Stock Exchange on April 15, raising over 1.5 billion HKD, making it one of the largest IPOs in the Hong Kong 18A sector in the past four years [2]. - The stock price peaked at 563.5 HKD in September, representing an increase of nearly 5 times from its IPO price of 94.6 HKD [2]. Group 2: Financial Performance - For the six months ending June 30, 2025, Innovent Biologics-B reported a revenue of 1.229 billion RMB, reflecting a year-on-year growth of 22.9%, primarily driven by external licensing and collaboration agreements [3]. - The company has a cash reserve of 3.75 billion RMB, sufficient to support its R&D activities for the next 3 to 5 years [3]. - Innovent Biologics-B is collaborating with BioNTech to advance its "ADC+IO" strategy, with several ADCs entering clinical trials [3]. Group 3: Strategic Focus - The company is dedicated to developing next-generation ADC innovative drugs for cancer and autoimmune diseases, with significant progress in pipeline development and business operations since early 2025 [3]. - Innovent Biologics-B aims to accelerate the global development and commercialization of its clinical projects to unlock their commercial value [3]. - The company plans to enhance its expertise in global research, clinical development, and regulatory affairs to drive future ADC innovations [3].
映恩生物官宣”回A” 港股上市以来最高涨幅接近5倍